Dr. Adithya Polasa is a seasoned computational chemist with over seven years of experience in protein research and biotherapeutics development. He currently serves as a Postdoctoral Fellow in Insilco Antibody Development at Boehringer Ingelheim, where he leads initiatives to design and optimize antibodies using cutting-edge computational methods. Dr. Polasa's expertise spans a wide range of technical skills, including molecular modeling, docking, molecular dynamics simulations, and machine learning. He is proficient in using various software tools like Autodock, MOE, Maestro, NAMD, VMD, PyMol, BioLuminate, TensorFlow, PyTorch, scikit-learn, Keras, Biopython, and more.

At Boehringer Ingelheim, Dr. Polasa has made significant contributions to Insilco antibody development projects. He has successfully collaborated with cross-functional teams, utilized advanced bioinformatics tools, and implemented machine learning algorithms to enhance predictive modeling for various antibody properties. His efforts have led to the optimization of antibody design processes and the identification of promising antibody candidates. Prior to joining Boehringer Ingelheim, Dr. Polasa held positions at the University of Arkansas and BINDINSILICO LLC. His research at the University of Arkansas focused on computational chemistry, where he developed a physics-based binding free energy estimator method and software. At BINDINSILICO LLC, he led the development of software applications for drug design and clinical development. Dr. Polasa's work has been recognized with several awards, including the NSF I-Crops award for market research and validation of business product. He has also published his research findings in renowned journals, establishing a reputation for thought leadership in the field of Insilico antibody development. Dr. Polasa continues to stay abreast of industry trends, ensuring the incorporation of the latest methodologies into antibody development practices. His commitment to innovation and excellence makes him a valuable asset in the field of biotherapeutics development.